Nanollose Limited (ASX:NC6) is pleased to announce that, following the recent successful pilot scale production of its Plant-Free NullarborTM fibre, Mr Gary Cass will increase his involvement in the Company's research and development. From 11 June 2018 Mr Cass will commence a full-time executive role within Nanollose and transition from non-executive director to executive director of the Company.
Oventus Medical Ltd (ASX:OVN) is pleased to attach a copy of the presentation that Founder and Clinical Director, Dr Chris Hart will deliver to investors this morning at the Thorney Sydney Investment Forum.
Oventus Medical Ltd (ASX:OVN) is pleased to announce positive interim data being presented today in a lecture at Macquarie University on a group of hard-to-treat obstructive sleep apnoea patients, who were studied in a sub-group as part of the ongoing "NeuRA Sydney study".
Nanollose Limited (ASX:NC6) is pleased to advise that it has received valid applications from Shareholders for 14,505,733 Options pursuant to the non-renounceable 1:4 entitlement option offer announced on 16 April 2018.
Nanollose Limited (ASX:NC6) is pleased to announce it has successfully manufactured its world first plant-free viscose-rayon fibre (NullarborTM) on a pilot scale. As a result of this increased scale, the Company has been able to create fabric for the first time, marking a significant breakthrough for Nanollose and the textile industry.
Oventus Medical Ltd (ASX:OVN) is pleased to announce the results of the OVEN-003 clinical trial study being conducted in Brisbane by the company, a randomised controlled clinical trial examining the treatment outcomes of oral appliance therapy with and without 'Oventus Airway Technology'.
Micro-X Limited (ASX:MX1) is delighted to announce that the Carestream DRX Revolution Nano Mobile X-Ray System designed by Micro-X has won a 2018 Good Design Award(R).
